Iris Pharma and RxGen Partner to Deliver Seamless and Superior Drug & Medical Devices Development Services in Ophthalmology
NICE, France & HAMDEN, Conn.--(BUSINESS WIRE)--Apr 19, 2012-- Iris Pharma, a leading ophthalmic preclinical and clinical contract research organization (CRO), and RxGen, a specialty preclinical CRO focused on the development and application of translational research models, have established a Strategic Alliance to offer fully integrated "bench-to-bedside" ophthalmology research services to the global pharmaceutical and biotechnology industries.
Under the newly forged transatlantic alliance, Iris Pharma can offer immediate access to RxGen's nonhuman primate ophthalmic research models and related preclinical in vivo services, via a flexible engagement model, that allows customers to benefit from the combined preclinical and clinical insight, capabilities, and expertise that RxGen and Iris Pharma collectively represent.
"Our alliance with RxGen is an exciting development for both companies. For Iris Pharma, this relationship allows us to add RxGen's unique capabilities and expertise to our existing portfolio of research and development services, completing the full value-chain required to bring a drug from bench to bedside", said Pierre-Paul Elena, CEO of Iris Pharma.
"The ability to offer integrated packages of services and a comprehensive and seamless program of preclinical and clinical drug development will improve our competitive position in the marketplace and generate significant value for our clients", said Yann Quentric, Head, Business Development & Marketing of Iris Pharma.
"Effectively translating discovery to approved therapeutic demands time and cost efficient program design and management, capitalizing on the best available preclinical test systems while maintaining a clear eye on the clinical pathway", said Matthew Lawrence, CEO of RxGen. "We look forward to working with Iris Pharma to match capabilities with needs to provide the lowest risk, highest return translational research solutions." "We are pleased to enter into an alliance with Iris Pharma, as we share a similar commitment to values critical to advancing Sponsor programs; scientific integrity, collaborative engagement and superior service", said Christopher Stanley, Chief Business Officer of RxGen.
"The unique combination of RxGen's in vivo ophthalmic capabilities in nonhuman primates and Iris Pharma's world leading position in ophthalmology uniquely positions us to provide superior innovative and adaptive services that will speed time to market for our customers".
About Iris Pharma: Iris Pharma is an independent CRO specializing in preclinical and clinical research services in ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris Pharma offers expertise in the development of ophthalmic drugs and ocular medical devices to the pharmaceutical industry and biotechnology companies worldwide. Iris Pharma services include proof of concept and GLP-compliant preclinical studies (safety, tolerance, pharmacokinetics, efficacy), bioanalysis, preclinical formulation, clinical trials and consulting services. Iris Pharma's research facilities are GLP compliant.
For more information, please visit www.iris-pharma.com.
About RxGen: RxGen, Inc. is a specialty preclinical CRO, providing innovative in vivo disease modeling and related preclinical research and development services to meet translational research needs of the global pharmaceutical and biotechnology industries. RxGen accelerates therapeutic and medical technology evaluation by the application of in vivo disease modeling and pharmacokinetic, pharmacodynamics and safety assessments, with deep therapeutic domain expertise in ophthalmology, central nervous system, metabolic and cardiac diseases and disorders.
RxGen's research facilities are AAALAC accredited and GLP compliant, supporting a range of services, from proof-of-concept through IND-enabling / regulatory studies.
For more information, please visit www.rx-gen.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid50243318&langen CONTACT: RxGen Contact: Chief Business Officer Christopher Stanley, (203) 498-9706 email@example.com or Iris Pharma Contact: Head, Business Development Yann Quentric, +33 4 93 59 49 59 firstname.lastname@example.org KEYWORD: UNITED STATES EUROPE NORTH AMERICA CONNECTICUT FRANCE INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY OPTICAL PHARMACEUTICAL SOURCE: Iris Pharma Copyright Business Wire 2012 PUB: 04/19/2012 10:33 AM/DISC: 04/19/2012 10:33 AM http://www.businesswire.com/news/home/20120419006133/